Clinical Trial Update: QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia [Phase 2, Phase 3]

View source ↗

Summary

Qilu Pharmaceutical's QL0911 is being studied in Phase 2 and Phase 3 trials for cancer treatment-induced thrombocytopenia. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• QL0911

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Cancer Treatment-Induced Thrombocytopenia | Phase 2, Phase 3 | Status: RECRUITING